



ZFW

DLA PIPER RUDNICK GRAY CARY US LLP

1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 3840-006-27

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/785,156
Applicant(s): Lakshman R. SEHGAL, et al.
Filing Date: February 25, 2004
For: THERAPEUTIC APPLICATIONS OF THROMBOMODULIN GENE
VIA VIRAL AND NON-VIRAL VECTORS
Group Art Unit: 1642
Examiner:

SIR:

Attached hereto for filing are the following papers:

Information Disclosure Statement
International Search Report
Form PTO-1449
Cited Documents (8)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DLA PIPER RUDNICK GRAY CARY US LLP

Ping Wang
Registration No.: 48,328

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Lakshman R. SEHGAL, et al. GROUP ART UNIT: 1642

SERIAL NUMBER: 10/785,156

FILED: February 25, 2004

FOR: THERAPEUTIC APPLICATIONS OF THROMBOMODULIN GENE VIA VIRAL AND NON-VIRAL VECTORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- ☒ Applicant(s) wish(es) to make of record the documents listed on the attached International Search Report and Form PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents.

RELATED CASES

- ☐ Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- ☒ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- ☐ without fee and within three months of the filing date of the application.
- ☐ without fee and within three months of the date of entry of the U.S. national stage.
- ☐ without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- ☒ without fee and with the appropriate certification above.
- ☐ without fee and with a new CPA application.
- ☐ without fee and with a Request for Continued Examination.
- ☐ with fee and before the mailing date of any Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- ☐ with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,

DLA PIPER RUDNICK GRAY CARY US LLP

Ping Wang

Registration No. 48,328

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO.	AUG 30 2005	SERIAL NO.
		3840-006-27	10/785,156	
		APPLICANT Lakshman R. SEHGAL, et al.		
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE	GROUP ART UNIT	
		February 25, 2004	1642	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2002/0068713	06/06/02	RADE, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AH	WO 96/06933	03/07/96	WIPO	X
	AI				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Waugh, et al., "Local Overexpression of Thrombomodulin for In Vivo Prevention of Arterial Thrombosis in a Rabbit Model", Circulation Research, Vol. 84, No. 1, pp. 84-92, 1999.
	AK	Waugh, et al., "Thrombomodulin Overexpression to Limit Neointima Formation", Circulation, Vol. 102, No. 3, pp. 332-337, 2000.
	AL	Vassalli, et al., "Gene therapy for arterial thrombosis", Cardiovascular Research, Vol. 19, No. 6, pp. 459-469, 1997.
	AM	Umana, et al., "Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination", Nature Biotechnology, Vol. 19, No. 6, pp. 582-585, 2001.
	AN	Wen, et al., "Human Thrombomodulin: Complete cDNA Sequence and Chromosome Localization of the Gene", Biochemistry, Vol. 26, pp. 4350-4357, 1987.
	AO	Borroni, et al., "Peripheral Blood Abnormalities in Alzheimer Disease: Evidence for Early Endothelial Dysfunction", Alzheimer Disease and Associated Disorders, Vol. 16, No. 3, pp. 150-155, 2002.
	AP	McKay, et al., "Gene Transfer Therapy in Vascular Diseases", Cardiovascular Drug Reviews, Vol. 19, No. 3, pp. 245-262, 2001.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.